E
Evofem Biosciences
Evofem Inc., a biotechnology company, develops reproductive and contraceptive care products for women worldwide
About Evofem Biosciences
Evofem Biosciences is a pioneering company in the sexual and reproductive healthcare sector, focusing on innovative, hormone-free contraceptive solutions. The company primarily serves women in the United States who are seeking non-hormonal, localized methods of birth control. Evofem operates in the pharmaceutical and healthcare markets, leveraging its extensive industry experience to introduce groundbreaking products that align with the growing trend towards natural and organic solutions. The business model revolves around the development, marketing, and sale of its flagship product, Phexxi, a hormone-free contraceptive gel. Revenue is generated through product sales, partnerships, and potentially through licensing agreements. Evofem's leadership team brings over 85 years of combined experience in healthcare and pharmaceuticals, ensuring robust strategic direction and execution. The company aims to empower women by providing them with more natural and effective contraceptive options, thereby addressing a significant gap in the market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- San Diego, United States
- Listing
- IPO 2014
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 32.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Fertility, Lifestyle, Biotechnology, Femtech, Sextech, Biotech and Pharma, Reproductive Health, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2023 | $100M | $100M | Aditxt | ↗ |
| POST IPO DEBTDebt | Feb 2023 | $1.4M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $20M | 0% | $491K | 2.4% |
| 2025 | $20M | +4.2% | $491K | 2.4% |
| 2024 | $19M | +6.3% | −$8.3M | -42.8% |
| 2023 | $18M | +8.2% | −$90M | -491.3% |
| 2022 | $17M | +104.2% | −$94M | -555.9% |
| 2021 | $8.2M | +1748.4% | −$133M | -1615% |
| 2020 | $446K | — | −$67M | -14990.1% |
Growth signals
Latest recorded traffic for Evofem Biosciences is 4K monthly website visits, up 33.3% over the last three months. Evofem Biosciences's team declined 27.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Adjuvant Capital
Series B and later3 investors entered at this stage
- RURusnano
Woodford Investment Management
PDL Biopharma
Other known investors2 additional known investors
Aditxt
Domain Associates
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Evofem Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evofem Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.